Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
ABOS 11.26.2024
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:7th Annual Evercore ISI HealthCONx Conference

About Gravity Analytica
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) --Acumen Pharmaceuticals, Inc.(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
The live webcast may be accessed under the Investors tab onwww.acumenpharm.comand will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visitwww.acumenpharm.com.
Investors:Alex Braunabraun@acumenpharm.com
Media:AcumenPR@westwicke.com
